Cargando…

In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity

BACKGROUND: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice since 2005 and has shown long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Badri, Marwa, Kilroy, Cara L., Shahar, Jacqueline Ifat, Tomah, Shaheen, Gardner, Hannah, Sin, Mallory, Votta, Jennie, Phillips-Stoll, Aliza, Price, Aaron, Beaton, Joan, Davis, Chandra, Rizzotto, Jo-Anne, Dhaver, Shilton, Hamdy, Osama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019312/
https://www.ncbi.nlm.nih.gov/pubmed/35464878
http://dx.doi.org/10.1177/20420188221093220
_version_ 1784689234096947200
author Al-Badri, Marwa
Kilroy, Cara L.
Shahar, Jacqueline Ifat
Tomah, Shaheen
Gardner, Hannah
Sin, Mallory
Votta, Jennie
Phillips-Stoll, Aliza
Price, Aaron
Beaton, Joan
Davis, Chandra
Rizzotto, Jo-Anne
Dhaver, Shilton
Hamdy, Osama
author_facet Al-Badri, Marwa
Kilroy, Cara L.
Shahar, Jacqueline Ifat
Tomah, Shaheen
Gardner, Hannah
Sin, Mallory
Votta, Jennie
Phillips-Stoll, Aliza
Price, Aaron
Beaton, Joan
Davis, Chandra
Rizzotto, Jo-Anne
Dhaver, Shilton
Hamdy, Osama
author_sort Al-Badri, Marwa
collection PubMed
description BACKGROUND: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice since 2005 and has shown long-term maintenance of weight reduction for 5 and 10 years. During the COVID-19 pandemic, the program went virtual using telemedicine and mobile health applications. AIMS: This retrospective pilot study aims to evaluate the effectiveness of a virtual model of an already established and successful in-person program for diabetes and weight management since 2005. METHODS: We evaluated 38 patients with diabetes and obesity enrolled in the Why WAIT program between February 2019 and December 2020. Sixteen participants were enrolled in virtual program (VP) and were compared with 22 participants who completed the latest two physical programs (PPs) before COVID-19. We evaluated changes in body weight, A1C, blood pressure (BP), and lipid profile after 12 weeks of ILI. RESULTS: Body weight decreased by −7.4 ± 3.6 kg from baseline in VP compared with −6.8 ± 3.5 kg in PP (p = 0.6 between groups). A1C decreased by −1.03% ± 1.1% from baseline in VP, and by −1.0% ± 1.2% in PP (p = 0.9 between groups). BP, lipid profile, and all other parameters improved in both groups with no significant difference between them. CONCLUSION: Virtual multidisciplinary ILI is as effective as the in-person intervention program in improving body weight, A1C, BP, and lipid profile, and in reducing the number of anti-hyperglycemic medications. Results from our study suggest that scaling the Why WAIT program in a virtual format to a larger population of patients with diabetes and obesity is feasible and is potentially as successful as the in-person program.
format Online
Article
Text
id pubmed-9019312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90193122022-04-21 In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity Al-Badri, Marwa Kilroy, Cara L. Shahar, Jacqueline Ifat Tomah, Shaheen Gardner, Hannah Sin, Mallory Votta, Jennie Phillips-Stoll, Aliza Price, Aaron Beaton, Joan Davis, Chandra Rizzotto, Jo-Anne Dhaver, Shilton Hamdy, Osama Ther Adv Endocrinol Metab Digital health and Diabetes: Where are we now? BACKGROUND: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice since 2005 and has shown long-term maintenance of weight reduction for 5 and 10 years. During the COVID-19 pandemic, the program went virtual using telemedicine and mobile health applications. AIMS: This retrospective pilot study aims to evaluate the effectiveness of a virtual model of an already established and successful in-person program for diabetes and weight management since 2005. METHODS: We evaluated 38 patients with diabetes and obesity enrolled in the Why WAIT program between February 2019 and December 2020. Sixteen participants were enrolled in virtual program (VP) and were compared with 22 participants who completed the latest two physical programs (PPs) before COVID-19. We evaluated changes in body weight, A1C, blood pressure (BP), and lipid profile after 12 weeks of ILI. RESULTS: Body weight decreased by −7.4 ± 3.6 kg from baseline in VP compared with −6.8 ± 3.5 kg in PP (p = 0.6 between groups). A1C decreased by −1.03% ± 1.1% from baseline in VP, and by −1.0% ± 1.2% in PP (p = 0.9 between groups). BP, lipid profile, and all other parameters improved in both groups with no significant difference between them. CONCLUSION: Virtual multidisciplinary ILI is as effective as the in-person intervention program in improving body weight, A1C, BP, and lipid profile, and in reducing the number of anti-hyperglycemic medications. Results from our study suggest that scaling the Why WAIT program in a virtual format to a larger population of patients with diabetes and obesity is feasible and is potentially as successful as the in-person program. SAGE Publications 2022-04-18 /pmc/articles/PMC9019312/ /pubmed/35464878 http://dx.doi.org/10.1177/20420188221093220 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Digital health and Diabetes: Where are we now?
Al-Badri, Marwa
Kilroy, Cara L.
Shahar, Jacqueline Ifat
Tomah, Shaheen
Gardner, Hannah
Sin, Mallory
Votta, Jennie
Phillips-Stoll, Aliza
Price, Aaron
Beaton, Joan
Davis, Chandra
Rizzotto, Jo-Anne
Dhaver, Shilton
Hamdy, Osama
In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
title In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
title_full In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
title_fullStr In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
title_full_unstemmed In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
title_short In-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
title_sort in-person and virtual multidisciplinary intensive lifestyle interventions are equally effective in patients with type 2 diabetes and obesity
topic Digital health and Diabetes: Where are we now?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019312/
https://www.ncbi.nlm.nih.gov/pubmed/35464878
http://dx.doi.org/10.1177/20420188221093220
work_keys_str_mv AT albadrimarwa inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT kilroycaral inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT shaharjacquelineifat inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT tomahshaheen inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT gardnerhannah inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT sinmallory inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT vottajennie inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT phillipsstollaliza inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT priceaaron inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT beatonjoan inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT davischandra inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT rizzottojoanne inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT dhavershilton inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity
AT hamdyosama inpersonandvirtualmultidisciplinaryintensivelifestyleinterventionsareequallyeffectiveinpatientswithtype2diabetesandobesity